Lupin receives approval from US FDA for Ganirelix Acetate Injection
The product will be manufactured at Lupin’s Nagpur facility in India
The product will be manufactured at Lupin’s Nagpur facility in India
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
Wockhardt has reported total income of Rs. 777 crores during the period ended September 30, 2023
Natco Pharma has reported total income of Rs. 1060.8 crores during the period ended September 30, 2023
Solara Active Pharma Sciences has reported total income of Rs. 426.42 crores during the period ended September 30, 2023
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
he company posted total income during Q2 FY24 at Rs. 12.86 crore
European operations' revenue grew 58.4% to Rs 599.7 crore
Subscribe To Our Newsletter & Stay Updated